Otenaproxesul is a Small Molecule owned by Antibe Therapeutics, and is involved in 10 clinical trials, of which 6 were completed, and 4 are planned.

ATB-346 is a derivative of naproxen which releases hydrogen sulfide. It suppresses COX-1 and COX-2 activity which leads anti-inflammatory activity. The drug candidate also inhibits leukocyte infiltration more effectively than naproxen. The hydrogen sulphide release decreases blood pressure by relaxation of smooth muscles of blood vessels through K ATP channel opening. ATB-346 suppresses the colonic prostaglandin synthesis and whole blood thromboxane synthesis. Inhibition of cyclooxygenase activity and release of H2S enhances the chemopreventative effect.

The revenue for Otenaproxesul is expected to reach a total of $569m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Otenaproxesul NPV Report.

Otenaproxesul was originated by Antibe Holdings and is currently owned by Antibe Therapeutics.

Otenaproxesul Overview

ATB-346 (otenaproxesul) is under development for the treatment of acute and chronic joint pain associated with osteoarthritis. It is administered orally. The drug candidate is a a non-steroidal anti-inflammatory, hydrogen sulfide releasing derivative of naproxen. Naproxen is an anti-inflammatory agent that targets COX-1 and COX-2. Naproxen carries a significant risk of serious gastrointestinal bleeding. This risk is reduced by the drug candidate by release of hydrogen sulphide. It was also under development for the treatment of colorectal cancer and melanoma.

Antibe Therapeutics Overview

Antibe Therapeutics (Antibe) formerly Ontario, is a biotechnology company. It designs and develops therapies for the treatment of pain and inflammation. The company’s lead compound ATB-346, an anti-inflammatory drug, is designed against chronic pain and inflammation. It is investigating ATB-352, a non-addictive analgesic, to treat post-operative pain; and ATB-340, a GI (gastro-intestinal) safe derivative of aspirin, targeting cardiovascular diseases. Antibe also offers regenerative medical devices for oral maxillofacial surgery through its subsidiary. The company supplies its products in Canada, China, Israel, Russia and South Korea. Antibe is headquartered in Toronto, Ontario, Canada.

The operating loss of the company was CAD25.5 million in FY2022, compared to an operating loss of CAD24.7 million in FY2021. The net loss of the company was CAD25.1 million in FY2022, compared to a net loss of CAD26.3 million in FY2021.

Quick View – Otenaproxesul

Report Segments
  • Innovator
Drug Name
  • Otenaproxesul
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Companies
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.